Yoonjin Cho

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman et al. · Blood · 2014 · 249 citations

Medicine, Oncology, Pharmacology +16

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Ian W. Flinn, Brad S. Kahl, John P. Leonard et al. · Blood · 2014 · 209 citations · Full text

Medicine, Oncology, Pharmacology +11

A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Andrew D. Zelenetz, Nicole Lamanna, Thomas J. Kipps et al. · Blood · 2014 · 29 citations

Medicine, Hematology, Oncology +10

Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Susan O’Brien, Nicole Lamanna, Thomas J. Kipps et al. · Blood · 2014 · 27 citations

Medicine, Oncology, Pharmacology +9

Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).

Jeffrey A. Jones, Tadeusz Robak, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2015 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +15